Liberia-U.S. clinical research partnership opens trial to test Ebola treatments
Initial study will evaluate experimental drug cocktail ZMapp.
In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases (NIAID) today launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study, which will be conducted in Liberia and the United States, is a randomized controlled trial enrolling adults and children with known Ebola virus infection.
This page was last updated on Friday, January 21, 2022